 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «12345678910» |
- | Sunlenca (lenacapavir) / Gilead
Journal: Case series of two persons living with HIV with detectable viral loads initiated then suppressed on cabotegravir/rilpivirine with lenacapavir. (Pubmed Central) - Jan 28, 2025
Initiation of intramuscular CAB/RPV with subcutaneous lenacapavir (LEN) injections was necessary with baseline resistance. A return to health with a BMI increase from <14
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
P3 data, Journal, Patient reported outcomes: Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir?+?Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study. (Pubmed Central) - Jan 17, 2025
P3
Most (90%, 382/425) questionnaire respondents preferred CAB?+?RPV LA vs. BIC/FTC/TAF (5%, 21/425). Switching to CAB?+?RPV LA was associated with significantly improved treatment satisfaction and relief from the fear of disclosure, anxiety surrounding adherence and reminder of HIV status.
- | Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Acceptability of Long-Acting Cabotegravir + Rilpivirine in a Large, Urban, Ambulatory HIV Clinic. (Pubmed Central) - Jan 14, 2025
Participants reported moderate injection pain, which improved with time. Results suggest injectable LA-CAB+RPV will be met with acceptability across diverse participant populations.
- ||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Adverse events: Therapeutic failure reported with HIV long-acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024. (Pubmed Central) - Jan 12, 2025
Results suggest injectable LA-CAB+RPV will be met with acceptability across diverse participant populations. Our findings suggest that healthcare professionals should have a heightened awareness of potential challenges with CAB/RPV administration, including TFs and dose omissions in real-world settings.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Observational data, Journal: Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort. (Pubmed Central) - Jan 12, 2025
Switching to cabotegravir and rilpivirine was not associated with a higher risk of loss of virological control among individuals without previous virological failure compared with oral ART. The high risk of loss of virological control among individuals with previous virological failure or an unsuppressed HIV-1 RNA at cabotegravir and rilpivirine initiation warrants more careful monitoring.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Adherence: Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine. (Pubmed Central) - Jan 10, 2025
Having office visit no-shows before switching to LAI CAB/RPV was associated with missed injection visits, and younger age was associated with both missed injection visits and late injections. Resources to reduce and manage missed injection appointments need to be considered when implementing LAI CAB/RPV.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Expanded Insights from a Case Study on Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnancy. (Pubmed Central) - Dec 27, 2024
Resources to reduce and manage missed injection appointments need to be considered when implementing LAI CAB/RPV. No abstract available
- | Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Cabotegravir and rilpivirine long acting injectables in a pregnant woman living with HIV. (Pubmed Central) - Dec 17, 2024
Despite placental transfer, no congenital malformations were noted. Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted.
- | Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Journal: Weight and metabolic changes with long-acting cabotegravir and rilpivirine or bictegravir/emtricitabine/tenofovir alafenamide. (Pubmed Central) - Dec 16, 2024
Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted. Standardized changes in weight, BMI, and body composition were minor and similar between participant switching to CAB+RPV LA Q2M or continuing BIC/FTC/TAF, with no clinically relevant changes in metabolic syndrome or insulin resistance.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Insights on Drug levels and Non-Sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Therapy. (Pubmed Central) - Dec 14, 2024
Standardized changes in weight, BMI, and body composition were minor and similar between participant switching to CAB+RPV LA Q2M or continuing BIC/FTC/TAF, with no clinically relevant changes in metabolic syndrome or insulin resistance. No abstract available
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Is Non-Sustained Viral Suppression with Long-Acting Cabotegravir and Rilpivirine Really Independent of Drug levels? (Pubmed Central) - Dec 14, 2024
No abstract available No abstract available
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Proviral HIV DNA sequencing to inform suitability for long-acting injectable cabotegravir/rilpivirine. (Pubmed Central) - Dec 6, 2024
We present our experience of sequencing proviral HIV DNA in 30 individuals to inform suitability for LAI ART, of whom 23 were considered suitable. In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition.
- || Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal, Adherence: Use of long-acting injectable cabotegravir/rilpivirine in people with HIV and adherence challenges. (Pubmed Central) - Dec 5, 2024
In conclusion, optimization of diagnostic tools such as proviral HIV DNA sequencing to confirm suitability for LAI ART would be a welcome addition. Creating programs that can support PWH with adherence challenges, their providers, and their clinics to use LA-CAB/RPV in service of sustained viral suppression is an urgent priority, particularly for PWH with CD4+ cell count <200?cells/mm3.
- | vesatolimod (GS-9620) / Gilead, Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity. (Pubmed Central) - Dec 5, 2024
We show efficient multidrug penetration in virus reservoirs and persisting rilpivirine in plasma for 2 years after the last dose. Our results document a type of virus remission that is achieved through early treatment initiation and provision of ultra long-lasting antiviral activity that persists after treatment cessation.
- | Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Early Implementation and Outcomes Among People with HIV who Accessed Long Acting Injectable-Cabotegravir/Rilpivirine at Two Ryan White Clinics in the U.S. South. (Pubmed Central) - Dec 2, 2024
At two clinics in the U.S. South, half of patients referred for LAI-CAB/RPV successfully accessed therapy nearly two years after U.S. drug approval. We identified barriers to uptake at the patient- and structural-levels, highlighting key areas to invest resource and personnel support to sustain and scale long-acting antiretroviral therapy programming.
- | Journal: Strategic use of salvage long-acting antiretrovirals in the setting of resistance. (Pubmed Central) - Nov 13, 2024
We identified barriers to uptake at the patient- and structural-levels, highlighting key areas to invest resource and personnel support to sustain and scale long-acting antiretroviral therapy programming. The case series reported here adds to literature supporting the notion that LA-CAB/RPV can be successfully used in patients who are viremic.
- |||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion date, Trial primary completion date, HEOR: CABO-LA: Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine (clinicaltrials.gov) - Nov 7, 2024
P=N/A, N=50, Not yet recruiting, Sponsor: Pontificia Universidad Catolica de Chile
The case series reported here adds to literature supporting the notion that LA-CAB/RPV can be successfully used in patients who are viremic. Trial completion date: Apr 2025 --> May 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir and rilpivirine reduce the risk of developing metabolic syndrome () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_438;
P
In our study, MS incidence decreased in PWH while receiving CAB+RPV. The use of CAB+RPV seemed to reduce the risk of developing MS after 1 year of follow up.
- rifampicin / Generic mfg.
Cabotegravir and rilpivirine injectable therapy with concomitant rifampicin treatment for a multidrug? resistant surgical site infection: management of antiretroviral treatment in real world using therapeutic drug monitoring () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_346;
Rapid switch to oral QD tenofovir/emtricitabine plus BID dolutegravir maintained effective antiretroviral levels and viral suppression during rifampicin co-administration. TDM is useful for managing complex drug interactions.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Concomitant administration of long?acting cabotegravir/rilpivirine and intramuscular antibiotics for the treatment of sexually transmitted infections: no evidence of pharmacodynamic interference () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_344;
Background: People living with HIV (PLWH) receiving cabotegravir/rilpivirine long-acting (CARLA) treatment are often at high risk of sexually transmitted infections (STIs) acquisition requiring intramuscular antibiotic injections...Study population was represented by PLWH receiving CARLA and benzathine penicillin, ceftriaxone or gentamycin to treat an STI... Concomitant intramuscular CARLA and antibiotic injections 8 days apart did not lead to inadequate antiretroviral and antibacterial responses.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Transforming HIV care: intramuscular bimonthly cabotegravir and rilpivirine for transgender people with HIV in Spain (RELATIVITY cohort) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_328;
This descriptive analysis highlights successful ART management of transgender people with HIV using CAB+RPV LA IM regimen. Further research is needed to understand broader treatment dynamics and outcomes in diverse transgender populations.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real?world utilization of cabotegravir/rilpivirine: an observational analysis of adherence and persistence using a patient support programme in Canada, preliminary results () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_295;
High adherence and persistence to CAB+RPV LA were observed among Canadian PWH receiving their injections through the PSP. Long-acting injectables may improve adherence and persistence, potentially ensuring the long-term treatment success.
- Pifeltro (doravirine) / Merck (MSD)
Safety and efficacy of dual doravirine plus lamivudine as a switch strategy in HIV patients with metabolic or renal issues () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_278;
DOR/3TC was safe and maintained viral suppression in heavily pre-treated patients with metabolic issues or renal deterioration on prior INSTI-based therapies, with reduced daily costs. These results may lead to larger comparative maintenance trials.
- bictegravir (GS-9883) / Gilead, Pifeltro (doravirine) / Merck (MSD), Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Safety and efficacy of doravirine plus tenofovir alafenamide/emtricitabine/bictegravir (TAF/FTC/BIC) in heavily pre?treated patients () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_277;
Prior ARV was INSTI based in 12 cases (52%), PI based in one (4%), and both INSTI and PI in 10 (43%), with additional maraviroc in three cases (13%)...Among the four subjects with persistent low-grade viraemia, two changed to long-acting cabotegravir/rilpivirine with virological success, and two maintained the combination with last available HIV RNA of 1.82 and 1.90 logs, respectively. The use of DOR plus TAF/FTC/BIC in heavily pre-treated patients was safe
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Treatment adherence and virological suppression in an outpatient cohort of people living with HIV (PLWH) on long?acting injectable HIV therapy () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_242;
Minor delays in injection schedules did not significantly impact virological outcomes, suggesting flexibility that could benefit adherence. These findings highlight the potential of LA-CAB/RPV to address adherence challenges and reduce stigmatization, supporting long-term viral suppression in real-world settings.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Patient?reported outcomes in switching to long?acting cabotegravir/rilpivirine: a real?life experience () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_238;
These findings highlight the potential of LA-CAB/RPV to address adherence challenges and reduce stigmatization, supporting long-term viral suppression in real-world settings. Thirty-six patients have joined it, via own mobile phone; 11 assigned female at birth (30.5%), with a median age of 47 years (range 29
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead
Antiretroviral treatment with BIC/FTC/TAF: where we come from and where we are going () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_237;
Antiretroviral therapy with BIC/FTC/TAF is the most commonly used ART in our hospital, being a safe therapy that is generally maintained over time and suitable for PLWH co-infected with HBV. The main reason for discontinuation is the participant's desire to switch to intramuscular therapies.
- Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J
Switching to long?acting intramuscular cabotegravir and rilpivirine in virologically suppressed PLHIV treated with dolutegravir/rilpivirine: a substudy from the RELATIVITY cohort (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_235;
In real-life settings, switching from DTG+RPV to CAB+RPV is safe and well tolerated. Our results suggest that in virologically suppressed PLHIV under treatment with DTG/RPV, previous genotyping results might not be necessary in order to switch to CAB+RPV.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Factors influencing the prescription of long?acting injectable dual therapy cabotegravir/rilpivirine in a Northwest Paris region cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_233;
In our single-centre cohort of PLHIV primarily born in sub-Saharan Africa and facing social disadvantages, the initiation of long-acting injectable cabotegravir/rilpivirine treatment is practitioner-driven. One-year tolerance and efficacy are favourable, demonstrating the feasibility of ensuring equal therapeutic opportunities for all.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Feasibility and satisfaction of interventions measures (FIM and HIVTISQ) of implementation long?acting (LA) CAB+RPV administration out of HIV units: the IMADART study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_230;
Background: Long-acting CAB and RPV has shown to be acceptable and feasible for the maintenance of HIV suppression for PWH. Treatment with CAB LA+RPV LA administered in different healthcare settings, outside of HIV units, is feasible and well tolerated for PWH, without compromising effectiveness and improving treatment satisfaction.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Efficacy and safety of long?acting cabotegravir + rilpivirine at All Saints Clinic in Wroclaw (Poland): real? life single?centre 2?year experience () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_228;
The few failures were due to unsuppressed viraemia at baseline or DDIs. Tolerance profile was acceptable by most patients with low overall drop-out rate of 5.31% (10/188).
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Results at month 7 of CABO?CHANCE study: real?world evidence (RWE) on the use of intramuscular cabotegravir plus rilpivirine long?acting (CAB+RPV LA) dosed every 2 months in viral suppressed people with HIV (PWH) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_227;
Tolerance profile was acceptable by most patients with low overall drop-out rate of 5.31% (10/188). This RWE study of CAB+RPV LA in PWH with extensive prior oral-ART and more than a decade of diagnosis, demonstrated that in the first 7 months of follow-up the LA regimen maintains viral suppression, with adverse effects decreasing in intensity, improved creatinine clearance, decreased IL-6 and positive influences health satisfaction and sleep quality.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Virological failure rate and emergent resistance in real?world studies evaluating long?acting cabotegravir and rilpivirine in people with baseline viral suppression () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_219;
Calculating an accurate VF rate using RWE is difficult due to heterogeneity of VF definition and study design. Resistance emerged commonly where VF occurred.
- Dovato (dolutegravir/lamivudine) / ViiV Healthcare
CARAVEL: evaluation of real?world effectiveness and sustainability of the two?drug regimen dolutegravir/lamivudine fixed?dose combination in treatment?naive adults and pre?treated adults who are virologically suppressed, in routine clinical care, in France: 2?year interim analysis results (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_213;
These real-world data demonstrated high virological success after 2 years on DTG/3TC in both TN-PLWH and PT-PLWH populations, without significant weight change. The main reason for DTG/3TC discontinuation remains the patient's request to switch to CAB/RPV-LA.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long?acting cabotegravir and rilpivirine in HIV individuals with a BMI over 30: a real?world study (RELATIVITY Cohort) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_212;
In a real-life setting, switching to long-acting CAB+RPV seems to be a viable option for individuals with a BMI over 30, lining up with other cohorts. Further investigation is needed.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
To describe the prevalence of virological failure and resistance patterns to long?acting cabotegravir? rilpivirine: a real?life single?centre cohort study () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_211;
Background: Long-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) is currently used as maintenance treatment for HIV-1. In our series, at week 28, the rate of VF (two consecutive VL >50 cp/ml) was low (1.25%), all of them were with low-level viraemias (<200 copies/ml) and the resistance mutations detected may reflect APOBEC activity and should be carefully interpreted by a resistance specialist.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Switching to LA CAB/RPV in virologically suppressed PLHIV: does knowing previous genotyping really matter? A substudy from the RELATIVITY cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_210;
These seem to line up with the results of the CARES study [1]. Nevertheless, a longer follow up is required to reach solid conclusions.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Use of long?acting cabotegravir and rilpivirine in a real?life setting: 12?month results of virological outcome, adherence, safety, durability, in the ANRS CO3 AquiVIH?NA Cohort?France () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_209;
In this large French cohort, 90% of patients continued CAB+RPV LA injections at month 12 and virological control was maintained. These results suggest that CAB+RPB LA injectable can be administered effectively during routine clinical care.
- Vocabria (cabotegravir oral) / ViiV Healthcare
Effectiveness of long?acting ART with cabotegravir/rilpivirine in the Icona Cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_208;
This analysis shows good short-term effectiveness of CAB-RPV LA, with a low rate of virological failure. A 13% probability of discontinuation overall and 10% for toxicity/adverse events emerged, higher than in phase III studies but similar to other real-life data.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real?life effectiveness, safety and acceptance of long?acting cabotegravir?rilpivirine: results from a large single?centre cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_206;
Of these, 318 (60%) and 99 (19%) participants reached w28 and w52 of follow-up, respectively. Baseline characteristics of the 318 participants who reached w28 are shown in Table 1.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir?rilpivirine long?acting injectable regimen: an analysis of the causes of interruption and impact of genotypic drug resistance in a multicentric cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_205;
CAB-RPV L-A regimen was well-tolerated. Respect of eligibility criteria and awareness of risk factors for VF plus strict monitoring of viro-immunological parameters are fundamental in reducing the risk of VF and the possible onset of new NNRTI/INSTI resistance mutations.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Central nervous system safety of long?acting cabotegravir/rilpivirine in patients with previous oral INSTI?related CNS toxicity () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_203;
Prior to C/R, 45% (N = 13) were on NNRTI-based therapies: TAF/FTC/RPV in 11 and TAF/FTC plus doravirine in two... In this cohort of heavily pretreated patients, the rate of CNS-related toxicity withdrawal was very low (1.5%), but the incidence of CNS toxicity and CNS-related withdrawals were significantly higher in patients with prior oral INSTI-related CNS adverse events.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long?acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_200;
Prior ARV were BIC/TAF/FTC (N = 3), and DTG/3TC and DTG/3TC/ABC one each...Concomitant immunosuppressants were: cyclosporin plus mycophenolate (N = 1), everolimus monotherapy (N = 1), everolimus plus prednisolone (N = 1), tacrolimus plus mycophenolate (N = 1); only the kidney recipient was on triple therapy with cyclosporin plus mycophenolate plus prednisone... LA with C/R may be considered in SOT patients as a safe and effective ARV.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Causes of discontinuation of long?acting cabotegravir and rilpivirine in clinical practice: results from the prospective multicentre SCOLTA cohort () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_197;
The frequency of LA CAB+RPV interruptions for AE was higher in this real-life cohort than in registrational trials, while high virological efficacy was seen, with 1% virological failure. To continue the active surveillance of AE in cohort studies will be critical to understanding the key to LA persistence.
- Vocabria (cabotegravir oral) / ViiV Healthcare
Efficacy and safety of long?acting intramuscular cabotegravir and rilpivirine in women: a substudy of the RELATIVITY cohort (Virtual) - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_196;
Although WLWH who switched to CAB+RPV had a worse profile regarding comorbidities and prevalence of AIDS, they do not seem to have a higher risk of VF compared to men, but discontinuation rate might be higher. A longer follow up is necessary to understand outcomes in this underrepresented and critical sub-population of PLWH treated with CAB+RPV.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Long?acting injectable cabotegravir and rilpivirine outcomes in HIV?positive migrants in Spain: do they have worse outcomes? () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_195;
Almost a third of patients switching to LAI CAB+RPV in this large Spanish cohort were migrants, mainly from Latin America. Migrant HIV-positive patients had twice the risk of discontinuing LAI CAB+RPV than Spanish-born patients and a higher risk of discontinuation due to side effects.
- Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real world outcomes of cabotegravir and rilpivirine for treating PLHIV in Spain: a multicentre, ambispective and nationwide study (the RELATIVITY cohort) () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_187;
The RELATIVITY cohort lines up with the results provided by randomized clinical trials and other real-life cohorts (ATHENA, OPERA, CARLOS) in terms of efficacy, tolerability, durability and virological failures. Longer follow-up is required to improve our knowledge regarding CAB/RPV.
- Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Similar virological outcomes and frequency of isolated viraemic events (blips, low?level viraemia and suspected virological failure) between oral and long?acting antiretroviral therapy: a pooled analysis of phase III/IIIb cabotegravir + rilpivirine long?acting studies () - Oct 26, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_170;
Viral blips and LLV were similarly infrequent with LA and oral ART and were not associated with CVF. Isolated SVF events were rare, with similar rates of subsequent CVF with LA and comparator oral ART.
- | Vemlidy (tenofovir alafenamide) / Gilead
Journal: Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide (TAF) in people with HIV. (Pubmed Central) - Oct 15, 2024
Replacing TAF with TDF in PWH led to a decrease in body weight and an improved lipid profile within 1 year. Weight changes were not observed among individuals who switched to DTG/3TC or long-acting CAB/RPV.
- Vocabria (cabotegravir oral) / ViiV Healthcare
Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine () - Oct 15, 2024 - Abstract #HIVGlasgow2024HIV_Glasgow_22;
Low RPV concentrations were observed in SP, whereas median total and protein-unbound concentrations exceeded the protein-adjusted IC90 (12 ng/ml) and the EC50 (0.27 ng/ml), respectively, in both RT and CVF. HIV-RNA suppression <20 copies/ml was maintained in BP, genital and rectal fluids after switching to LA CAB+RPV.